当前位置：
X-MOL 学术
›
Mol. Pharmaceutics
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
RNAi Nanotherapeutics for Treatment of Glioblastoma Multiforme.
Molecular Pharmaceutics ( IF 4.5 ) Pub Date : 2020-09-09 , DOI: 10.1021/acs.molpharmaceut.0c00709 Prabhjeet Singh 1 , Aditi Singh 1 , Shruti Shah 1 , Jalpa Vataliya 1 , Anupama Mittal 1 , Deepak Chitkara 1
Molecular Pharmaceutics ( IF 4.5 ) Pub Date : 2020-09-09 , DOI: 10.1021/acs.molpharmaceut.0c00709 Prabhjeet Singh 1 , Aditi Singh 1 , Shruti Shah 1 , Jalpa Vataliya 1 , Anupama Mittal 1 , Deepak Chitkara 1
Affiliation
|
Nucleic acid therapeutics for RNA interference (RNAi) are gaining attention in the treatment and management of several kinds of the so-called “undruggable” tumors via targeting specific molecular pathways or oncogenes. Synthetic ribonucleic acid (RNAs) oligonucleotides like siRNA, miRNA, shRNA, and lncRNA have shown potential as novel therapeutics. However, the delivery of such oligonucleotides is significantly hampered by their physiochemical (such as hydrophilicity, negative charge, and instability) and biopharmaceutical features (in vivo serum stability, fast renal clearance, interaction with extracellular proteins, and hindrance in cellular internalization) that markedly reduce their biological activity. Recently, several nanocarriers have evolved as suitable non-viral vectors for oligonucleotide delivery, which are known to either complex or conjugate with these oligonucleotides efficiently and also overcome the extracellular and intracellular barriers, thereby allowing access to the tumoral micro-environment for the better and desired outcome in glioblastoma multiforme (GBM). This Review focuses on the up-to-date advancements in the field of RNAi nanotherapeutics utilized for GBM treatment.
中文翻译：
用于治疗多形性胶质母细胞瘤的 RNAi 纳米疗法。
用于 RNA 干扰 (RNAi) 的核酸疗法通过靶向特定分子途径或癌基因，在治疗和管理几种所谓的“不可成药”肿瘤方面受到越来越多的关注。合成核糖核酸 (RNA) 寡核苷酸，如 siRNA、miRNA、shRNA 和 lncRNA，已显示出作为新疗法的潜力。然而，此类寡核苷酸的递送受到其生理化学（如亲水性、负电荷和不稳定性）和生物制药特征（体内血清稳定性、快速的肾脏清除、与细胞外蛋白的相互作用以及细胞内化的障碍），这显着降低了它们的生物活性。最近，一些纳米载体已经发展成为适合寡核苷酸递送的非病毒载体，已知它们可以有效地与这些寡核苷酸复合或偶联，并克服细胞外和细胞内的障碍，从而更好地进入肿瘤微环境。多形性胶质母细胞瘤 (GBM) 的预期结果。本综述重点关注用于 GBM 治疗的 RNAi 纳米疗法领域的最新进展。
更新日期：2020-11-02
中文翻译：
用于治疗多形性胶质母细胞瘤的 RNAi 纳米疗法。
用于 RNA 干扰 (RNAi) 的核酸疗法通过靶向特定分子途径或癌基因，在治疗和管理几种所谓的“不可成药”肿瘤方面受到越来越多的关注。合成核糖核酸 (RNA) 寡核苷酸，如 siRNA、miRNA、shRNA 和 lncRNA，已显示出作为新疗法的潜力。然而，此类寡核苷酸的递送受到其生理化学（如亲水性、负电荷和不稳定性）和生物制药特征（体内血清稳定性、快速的肾脏清除、与细胞外蛋白的相互作用以及细胞内化的障碍），这显着降低了它们的生物活性。最近，一些纳米载体已经发展成为适合寡核苷酸递送的非病毒载体，已知它们可以有效地与这些寡核苷酸复合或偶联，并克服细胞外和细胞内的障碍，从而更好地进入肿瘤微环境。多形性胶质母细胞瘤 (GBM) 的预期结果。本综述重点关注用于 GBM 治疗的 RNAi 纳米疗法领域的最新进展。
京公网安备 11010802027423号